BERKELEY, CA USA (Press Release) - May 15, 2013 -
Xofigo approved three months ahead of schedule under priority review program
WHIPPANY, NJ USA (Press Release) - July 17, 2013 - Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomaticProstate CAncer) trial of its drug Xofigo® (radium Ra 223 dichloride) in castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases and no known visceral metastatic disease are published in the July 18 issue of the New England Journal of Medicine (NEJM).
Login to update email address, newsletter preferences and use bookmarks.
Email
Password